Elsevier

Endocrine Practice

Volume 22, Supplement 7, December 2016, Pages 14-20
Endocrine Practice

Individualizing Lifestyle Therapy for Patients with Obesity

https://doi.org/10.1016/S1530-891X(20)43231-8Get rights and content

Section snippets

The Role and Benefits of Pharmacotherapy in Obesity Management

Although lifestyle intervention alone often results in weight loss adequate to alleviate health symptoms in some patients, medications can help patients who are struggling to achieve weight-loss goals. Weight-loss medications, which should always be used as an add-on to a lifestyle intervention program, enhance the patient’s ability to adhere to a reduced- calorie meal plan and increase weight loss 49., 50., 51., 52., 53., 54.. The addition of medication to a lifestyle intervention provides

Strategies to Develop Individualized Pharmacotherapy Regimens

General prescribing principles apply to all weight-loss medications used to treat patients with obesity (Fig. 7). Medication should be considered when the patient who has a BMI of 27 to 29.9 kg/m2 and one obesity-related complication or when a patient has a BMI > 30 kg/m2. Medication use should be initiated when lifestyle therapy alone fails and the patient progressively gains weight or has no clinical improvement in weight-related complications (56). If a patient has weight gain following

Three Domains for Pharmacologic Individualization

When considering treatment for a patient with overweight or obesity, it is important to consider patient, biologic, and pharmacotherapeutic factors (Table 3). Understanding patient factors enables the physician to develop a weight-loss plan with a greater likelihood of success. Biologic factors affect the success of a weight-loss plan and need to be taken into account when setting realistic weight-loss goals. The weight- related complications being treated also need to be considered, as the

Summary and Conclusions

When creating a therapeutic plan to reduce weight and alleviate weight-related complications in patients with overweight or obesity, physicians must take into account the patient’s unique presentation, including concurrent disease, medical history, lifestyle preferences, psychological issues, and other patient-related factors, in order to individualize lifestyle therapy and pharmacotherapy that will enable the patient to achieve successful health outcomes. Effective patient-physician

Self-Assessment Test

Supplement from a live satellite symposium conducted in Orlando, Florida, on May 26, 2016, in conjunction with the AACE 25th Annual Scientific and Clinical Congress. To receive CME credit, please enter the self-assessment test answers and complete the activity evaluation. Credit is awarded to test scores > 70%. There are no fees to participate and receive credit. CME certificates will be mailed within 4 to 6 weeks of receipt of the self-assessment test and evaluation. Mail, email or fax the

First page preview

First page preview
Click to open first page preview

REFERENCES (82)

  • A.J. Garber et al.

    American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement--executive summary

    Endocr Pract.

    (2013)
  • K.M. Gadde et al.

    Effects of low-dose, controlled-release, phen- termine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

    Lancet.

    (2011)
  • F.L. Greenway et al.

    COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    Lancet.

    (2010)
  • W.T. Garvey et al.

    American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease

    Endocr Pract.

    (2014)
  • W.T. Garvey et al.

    American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on obesity: building an evidence base for comprehensive action

    En- docr Pract.

    (2014)
  • National Institute of Diabetes and Digestive and Kidney Diseases

    Overweight and Obesity Statistics

    (2012)
  • J. Levi et al.

    F as in fat: how obesity threatens America’s future

    The Robert Wood Johnson Foundation

    (2012)
  • NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants

    Lancet

    (2016)
  • G.A. Bray

    Diabetes and obesity-time bombs to be defused

    Diabetes Care.

    (2015)
  • W.H. Dietz et al.

    STOP Obesity Alliance

    Why weight? A guide to discussing obesity and health with your patients

    (2014)
  • P. Bjorntorp et al.

    The metabolic syndrome-- a neuroendocrine disorder?

    Br J Nutr.

    (2000)
  • American Medical Association House of Delegates

    American Medical Association House of Delegates. Resolution 420(A13) Recognition of diabetes as a disease

    (2016)
  • Institute for Clinical Systems Improvement (ICSI)

    Prevention and management of obesity (mature adolescents and adults)

    (2016)
  • H.M. Seagle et al.

    Position of the American Dietetic Association: weight management

    J Am Diet Assoc.

    (2009)
  • R.C. Rabin

    Doctors and patients, not talking about weight

    New York Times

    (March 16, 2010)
  • D.A. Lawlor et al.

    Can general practitioners influence the nation’s health through a population approach to provision of lifestyle advice?

    Br J Gen Prac.

    (2000)
  • S. Koven

    Diet drugs work: why won’t doctors prescribe them?

    The New Yorker

    (December 4, 2013)
  • E.E. Kershaw et al.

    Adipose tissue as an endocrine organ

    J Clin Endocrinol Metab.

    (2004)
  • G.R. Hajer et al.

    Adipose tissue dysfunction in obesity, diabetes, and vascular diseases

    Eur Heart J.

    (2008)
  • R.F. Hamman et al.

    Effect of weight loss with lifestyle intervention on risk of diabetes

    Diabetes Care.

    (2006)
  • X. Pi-Sunyer

    The Look AHEAD trial: a review and discussion of its outcomes

    Curr Nutr Rep.

    (2014)
  • J.L. Kraschnewski et al.

    A silent response to the obesity epidemic: decline in US physician weight counseling

    Med Care.

    (2013)
  • R.F. Kushner et al.

    Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm

    Obesity (Silver Spring).

    (2013)
  • R.E. Post et al.

    The influence of physician acknowledgment of patients’ weight status on patient perceptions of overweight and obesity in the United States

    Arch Intern Med.

    (2011)
  • T.A. Wadden et al.

    What’s in a name? Patients’ preferred terms for describing obesity

    Obes Res.

    (2003)
  • M. Vallis et al.

    Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care

    Can Fam Physician.

    (2013)
  • E.A. Sherson et al.

    A review of the use of the 5 A’s model for weight loss counseling: differences between physician practice and patient demand

    Fam Pract.

    (2014)
  • S. Rollnick et al.

    Motivational interviewing

    BMJ.

    (2010)
  • M.E. Lean et al.

    Garth- waite PH. Obesity, weight loss and prognosis in type 2 diabetes

    Diabet Med.

    (1990)
  • D.E. Schotte et al.

    The effects of weight reduction on blood pressure in 301 obese patients

    Arch Intern Med.

    (1990)
  • G.D. Foster et al.

    Weight and metabolic outcomes after 2 years on a low- carbohydrate versus low-fat diet: a randomized trial

    Ann Intern Med.

    (2010)
  • Cited by (0)

    View full text